
NASA Budget Cuts Could Have A Martian Silver Lining
Iceland is an astrobiologist's dream — rife with active volcanic landscapes, basaltic plains and lava tunnels that has repeatedly been used by NASA as a stand in for Mars. But at last week's European Astrobiology Institute's BEACON 25 conference in Reykjavik, most attendees were clamoring to get their hands on samples of the real thing.
NASA's Perseverance rover — now perched on the rim of Jezero Crater in Mars' southern highlands, has collected some 41 subsurface samples just waiting for a sample return mission to retrieve them back to Earth. But that doesn't seem likely to happen anytime soon.
Yet at least one planetary scientist refuses to be hamstrung by focusing on the funding hole in the Martian sample return donut. That's because even if there's a decades-long delay in getting the samples back to Earth, Perseverance's Radioisotope Thermoelectric Generator has plenty of life left and can potentially use the time to explore beyond Jezero Crater's rim.
Perseverance has dropped samples on the crater floor, but it has more samples now from the rim in its storage cache, Adomas Valantinas, a Brown University planetary scientist, tells me in Reykjavik. But it would have to return back to the crater floor, where the lander from the Mars sample return mission would touch down, because it's flat and is a good area for landing with no strong winds, he says.
Thus, in what could be a bit of serendipity, if the sample return is postponed indefinitely, Perseverance is free to roam beyond the rim of Jezero Crater.
Why beyond the rim?
Beyond the crater rim, there is this area called Nili Planum, a flat terrain that contains a lot of volcanic minerals, says Valantinas. If you go 30 to 50 km south, also beyond the rim in the northeast Syrtis region there are a lot of minerals that could have been formed by hydrothermal activity, he says. So, going south beyond the rim, you also have rocks that are potentially 4.1-billion-years-old where the potential for a habitable environment was even greater, says Valantinas.
As noted in his Reykjavik presentation, Valantinas and colleagues' findings have specifically been researching the 3.8-billion-year-old, 45-km-wide Jezero impact crater. The Jezero impactor hit about the same time that life first formed on Earth and when liquid water was stable on the Martian surface.
We used observations from NASA's Mars Reconnaissance Orbiter to understand the composition of the Jezero Crater rim, and we also did numerical simulations to understand how materials moved post impact and where they were deposited, says Valantinas. Ancient Rocks
Our study basically shows that the materials in the Jezero rim are diverse, and they may represent a habitable environment 3.8 billion years ago, because they not only contain primary minerals, but secondary alteration minerals when liquid water was present, says Valantinas.
Why is geological diversity important?
Diversity probably means more complex mineralogy and more complex chemistry, which could mean a more habitable environment, says Valantinas. If we were seeing the same three or four different minerals and no diversity in the composition, that would probably mean it wasn't a habitable environment, he says.
What kind of atmosphere did Mars have when the Jezero impactor hit?
The atmosphere was probably thick enough for liquid water to exist on the surface, says Valantinas. So, it probably had some nitrogen, carbon dioxide and probably some water vapor, he says.
Perseverance has already found some of the oldest rocks ever sampled on the Martian surface. But we need to push the envelope of what we really understand about the history of the red planet, which has both frustrated and perplexed even its most ardent advocates. That's why retrieving these samples for analysis in the best labs the world has to offer is so crucial to humanity's understanding of solar system science.
Icelandic landscape near the boundary between the North American and Eurasian tectonic plates. Bruce Dorminey Radiation Threat
There's also the potential that a decades-long delay in retrieving the samples that the Perseverance rover has collected could be affected by incoming cosmic radiation. Most of the samples are now safely positioned inside the rover but there are others that have been left on the surface near the landing site of a future sample return mission.
The idea being that if for whatever reason, the rover malfunctions and can't make it back to the Jezero Crater basin, there would still be a few samples prepositioned on the surface which a return lander could retrieve for the journey back to Earth.
Perseverance collected the samples themselves using a coring mechanism to a depth of only about 7 cm in depth. But now these sample cores are above ground they are much more susceptible to the effects of surface radiation.
Even at 7 cm of subsurface depth, you must think about corpuscular (subatomic particle) radiation and galactic radiation, which is also bombarding the surface, Jean-Pierre De Vera, a planetary scientist at the German Aerospace Center (DLR), tells me in Reykjavik. And after several years inside the rover on the surface, the samples' original subsurface organics could certainly be changed, says De Vera.
I'll be in the Icelandic Highlands for a week sampling iron oxide minerals in every kind of environment, from cold springs to hot springs and rivers, says Valantinas. The idea is to use Iceland as an analog for processes that could have happened on ancient Mars, he says.
Why is Iceland better than anywhere else?
Iceland is a volcanic island with basalt as a kind of the bedrock material, says Valantinas. So, the weathering of the basalts leads to secondary minerals in Iceland, and similar secondary minerals are observed on Mars, he says.
Meanwhile, astrobiologists worldwide are hoping that the Mars samples can find their way back to Earth in a timely manner.
As for why the Mars is so important to astrobiology?
We're busy looking for life on exoplanets and we have Mars here that's within reach, Benton Clark, senior research geochemist at the Space Science Institute in Boulder, Colo. tells me in Reykjavik. All we need to do is to bring those samples back and we're going to learn so much more; maybe detect evidence of life, says Clark. Forbes Why Europe May Beat NASA To Life On Mars By Bruce Dorminey Forbes How NASA Can Avoid A False Positive Mars Microfossil Detection By Bruce Dorminey
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
INBRAIN Neuroelectronics Reports Interim Analysis of First-in-Human Study of Graphene Brain-Computer Interface
Graphene-based BCI demonstrates high-resolution brain decoding and mapping in patients undergoing tumor resection at the Manchester Centre for Clinical Neurosciences Initial four patient cohort has shown no safety concerns to date that would prevent the completion of this first-in-human study. BARCELONA, Spain, July 29, 2025--(BUSINESS WIRE)--INBRAIN Neuroelectronics today announced the interim analysis of findings from the world's first-in-human clinical study of its graphene-based brain-computer interface (BCI) technology. The study, sponsored by the University of Manchester and conducted at the Manchester Centre for Clinical Neurosciences (Northern Care Alliance NHS Foundation Trust), is evaluating the safety and functional performance of graphene-based electrodes when used during surgery for resection of brain tumors. The primary objective of the study (NCT06368310) is to assess the safety of INBRAIN's brain-computer interface (BCI) during brain tumor surgery. Secondary objectives include evaluating the quality of neural signals captured by the device, its ability to deliver targeted brain stimulation, the consistency of its performance throughout the procedure, and its overall suitability for use in the neurosurgical operating room. A total of 8 to 10 patients are expected to be enrolled to validate the safety and functional performance of the graphene-based BCI. The study design included an interim analysis after the first four patients had been recruited to ensure patient safety and data quality. Interim analysis of the results from the first cohort of four patients enrolled in the study demonstrated no device-related adverse events, a key component of the primary endpoint of the study. During awake language mapping, the device captured distinct high gamma activity linked to different phonemes, the smallest units of sound in speech, showcasing exceptional spatial and temporal resolution, even with micrometer-scale contacts. The ultra-thin, sub-micrometer graphene electrodes also proved compatible with commercially available, CE-marked electrophysiology systems, reliably recording real-time brain signals throughout the surgical procedures. "The ability to detect high-frequency neural activity with micrometer-scale precision opens new possibilities for understanding brain-tumor interactions and broader brain function in neuro-related disorders," said Mr. David Coope, Chief Investigator and Consultant Neurosurgeon at the Manchester Centre for Clinical Neurosciences, the Geoffrey Jefferson Brain Research Centre and the University of Manchester. "This technology could be transformative, not only for improving surgical outcomes but for unlocking new treatment pathways." Throughout the procedures, INBRAIN's BCI enabled high-resolution brain signal monitoring, addressing one of the most pressing challenges in neurosurgery: achieving precise tumor removal while preserving essential functions such as speech, movement, and cognition. The device was used in parallel with standard clinical monitoring tools, maintaining consistent performance across the surgical window. "This milestone demonstrates that graphene-based brain-computer interfaces can be deployed in the operating room and deliver a level of neural fidelity not achievable with traditional materials," said Carolina Aguilar, CEO and Co-Founder, INBRAIN Neuroelectronics. "We're moving toward a future where neurosurgeons and neurologists can rely on real-time, high-definition brain data to guide personalized interventions." INBRAIN's platform is powered by ultra-flexible, thin-film graphene semiconductors that conform more precisely to the brain surface than conventional strip electrodes. The BCI features high-density, multiscale, bidirectional contacts for superior decoding and modulation, and reduced graphene oxide (rGO) nanoporous matrices that enhance sensitivity and signal resolution. In preclinical studies, the GCI significantly outperformed platinum-based electrodes in detecting high gamma frequencies (80–130 Hz) critical for speech decoding, with statistical significance (p < 0.01). Clinical Advantages Graphene technology offers several benefits for neurosurgical procedures. It enhances surgical precision by enabling smaller and more densely packed electrodes, allowing surgeons to define and preserve critical functional areas during tumor resection. Its flexibility enables accurate decoding and mapping in anatomically complex or hard-to-access brain regions, including the walls of the tumor resection cavity. Additionally, the device's ability to decode high-frequency activity offers huge scientific opportunities including the potential to reveal in situ interactions between glioma cells and neurons, offering potential insights into new therapeutic targets for halting tumor progression. "We're not delivering incremental innovation, we're enabling entirely new capabilities," said Kostas Kostarelos, Co-Founder of INBRAIN and Chief Scientific Investigator of the study and Professor of Nanomedicine at the University of Manchester, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) in Barcelona, and Programme Lead for the Next Generation Therapeutics Theme of the National Institute for Health and Care Research (NIHR) Manchester Biomedical Research Centre (BRC). "This convergence of advanced materials science, neuroscience, and AI is shaping the future of real-time, precision neurology." As the first safety study of a graphene-based neural interface in humans, this study marks a foundational step toward the development of BCI therapeutic systems for chronic neurological diseases, pioneering a new era of real-time, precision neurology. About INBRAIN Neuroelectronics INBRAIN Neuroelectronics is pioneering real-time precision neurology with the world's first graphene-based brain-computer interface (BCI) therapeutics platform. Our technology combines precise BCI decoding with micrometric modulation to deliver adaptive, personalized treatments for conditions such as Parkinson's disease, epilepsy, and stroke rehabilitation. By providing continuous real-time monitoring and autonomous therapy adjustments, our AI-driven platform maximizes therapeutic outcomes while minimizing side effects. Through strategic collaborations, including with Merck KGAa and our subsidiary INNERVIA Bioelectronics, we are extending our innovative solutions to peripheral nerve and systemic disease applications, unlocking the potential of neurotechnology and bioelectronics. For more information, visit and follow us on LinkedIn. About Northern Care Alliance (NCA) Northern Care Alliance NHS Foundation Trust provides hospital and community healthcare services in Salford, Oldham, Bury and Rochdale. Our dedicated team of around 20,000 staff delivers high standards of care and experience excellence to over one million people across Greater Manchester and beyond, working together to save lives and improve lives. More information about the NCA can be found at About the National Institute for Health and Care Research (NIHR) The mission of the National Institute for Health and Care Research (NIHR) is to improve the health and wealth of the nation through research. We do this by: Funding high quality, timely research that benefits the NHS, public health and social care; Investing in world-class expertise, facilities and a skilled delivery workforce to translate discoveries into improved treatments and services; Partnering with patients, service users, carers and communities, improving the relevance, quality and impact of our research; Attracting, training and supporting the best researchers to tackle complex health and social care challenges; Collaborating with other public funders, charities and industry to help shape a cohesive and globally competitive research system; Funding applied global health research and training to meet the needs of the poorest people in low and middle income countries. NIHR is funded by the Department of Health and Social Care. Its work in low and middle income countries is principally funded through UK international development funding from the UK government. About the NIHR Manchester Biomedical Research Centre (BRC) The NIHR Manchester Biomedical Research Centre (BRC) transforms scientific breakthroughs into diagnostic tests and life-saving treatments for patients. NIHR Biomedical Research Centres (BRCs) are collaborations between NHS organisations and universities. They bring together academics and clinicians to translate scientific discoveries into potential new treatments, diagnostics and technologies. Manchester BRC is hosted by Manchester University NHS Foundation Trust and The University of Manchester – in partnership with five NHS trusts; Blackpool Teaching Hospitals NHS Foundation Trust, The Christie NHS Foundation Trust, Greater Manchester Mental Health NHS Foundation Trust, Lancashire Teaching Hospitals NHS Foundation Trust, and the Northern Care Alliance NHS Foundation Trust. About The University of Manchester The University of Manchester is recognised globally for its pioneering research, outstanding teaching and learning, and commitment to social responsibility. The Russell Group institution is ranked the 6th best university in the UK and 38th in the world (Academic Ranking of World Universities). A truly international university, its community includes more than 44,000 students, 12,000 staff, and 500,000 alumni from 190 countries. Together, they are tackling the world's biggest challenges – the University's social and environmental impact is ranked in the top ten globally (Times Higher Education Impact Rankings). The University is a powerhouse of research and discovery; 25 Nobel laureates are among its former staff and students; and it was ranked fifth for research power – the quality and scale of research and impact – in the UK government's Research Excellence Framework (REF) 2021. The institution is the most popular in the UK for undergraduate applications (UCAS 2021 cycle), and it is the it is the most targeted university by the UK's leading employers (The Graduate Market, 2023). View source version on Contacts Media Kimberly HaKKH Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


New York Times
an hour ago
- New York Times
When Coke and Pepsi Fought for Soft Drink Supremacy in Space
In space travel, the firsts are often what matter most: the first woman in orbit and the first man to walk on the moon, or, less famously, the first time astronauts grabbed a wobbling satellite with their hands. Yet in the 1980s, America's two biggest soft drink companies raced for another milestone: to serve the first fizzy drink in orbit. One of the greatest excesses of the cola wars happened as NASA was transitioning from the prestige-driven program of the Apollo years toward our modern era of commercial spaceflight, which has dominated by companies willing to land a Nokia 4G/LTE communications system on the moon, or launch a mannequin-driven Tesla Roadster into deep space. To the Coca-Cola Company and PepsiCo, the commercially minded shuttle program was a perfect marketing opportunity. Forty years on, a NASA astronaut remembers positive moments of the soft drink space race. 'We did our job and it was kind of fun,' said Loren Acton, a space shuttle payload specialist. But others who faced the cola giants' rivalry were less charitable. 'Of all the things that were done on the shuttle, the one that caused the most aggravation was the goddamn cola war,' said James M. Beggs, the NASA administrator in the early 80s. Mr. Beggs died in 2020, but was quoted in a 1986 interview by Joseph Trento, a reporter, in Mr. Trento's book 'Prescription for Disaster: From the Glory of Apollo to the Betrayal of the Shuttle.' The cola companies earned Mr. Beggs's frustration. Coca-Cola and PepsiCo would take their space race to the upper levels of NASA, and all the way to the White House. Though spaceflight is difficult, the companies' earthbound rivalries proved even more difficult to overcome. Want all of The Times? Subscribe.


Medscape
2 hours ago
- Medscape
Novel Long-term Findings for Post-HRT Fracture Risk
Bone fracture risk for women coming off menopausal hormone replacement therapy (HRT) increases sharply before showing a reduced long-term fracture risk compared with women who never took hormones, new data from a study published in The Lancet indicated. 'It's reassuring that long term, you didn't seem to be worse off if you had taken hormones in the past. And it reconfirms that when you first go off the hormones, you're going to lose some benefit, which can translate into higher fracture risk and that needs attention,' certified menopause specialist Deborah Kwolek, MD, told Medscape Medical News . 'I think this is a good wake-up call that we need to pay more attention to women's bone health starting at menopause,' said Kwolek, assistant professor at Harvard Medical School in Boston and founding lead of the Mass General Women's Health and Sex and Gender Medicine Program. Data on 3 Million Women Included Researchers, led by Yana Vinogradova, PhD, with the Centre for Academic Primary Care at the University of Nottingham in the United Kingdom, assessed the health records of 648,747 women aged 40 years and older, who were registered with a primary care practice between January 1, 1998, and February 28, 2023, and had a first record for any fracture. These women were matched at the fracture index date with up to five female controls (2,357,125 women) with no fracture history, who were the same age and registered at the same general practice. Menopausal HRT-related fracture risks were assessed using conditional logistic regression adjusted for demographics, family history, menopausal symptoms, comorbidities, and other medications. The study was powered to investigate all HRT prescriptions containing estrogen and progestogen in the British National Formulary and to assess risk estimates for up to 25 years after stopping therapy. Reduced Fracture Risk in Older Age 'Our study suggests that, even after stopping menopausal hormone therapy, women could benefit from notably reduced fracture risk in older age. This likelihood holds for those who might have used menopausal hormone therapy for shorter periods because of concerns such as breast cancer,' the authors wrote. These results differ in some ways from some previous large studies, including the Women's Health Initiative post-trial study, which followed 15,187 women for 5 years but found no increased fracture risk after stopping hormone therapy. Kwolek explained that estrogen has long been known to be important for bone health, especially in the perimenopausal to menopausal transition and estrogen could prevent the bone loss that increases right at menopause. But the general understanding had been that when women go off estrogen the benefits go away. 'We had been saying more recently that when women go off estrogen, there should be a plan for how their bone health may be addressed, potentially with medication and close monitoring,' Kwolek said. Consider Baseline Fracture Risk She added that it's important to consider what a patient's fracture risk is to start with. For a young, healthy woman who doesn't have osteoporosis, it's probably not terribly significant if her risk goes up a bit going off the hormones, Kwolek said, but 'for a woman who's 70 and she comes off her hormones and already has osteoporosis, the effects may be more significant,' Kwolek said. 'Maybe at that time you might start another medication to strengthen the bone.' She cautions against seeing the temporary increase in fracture risk after stopping the hormones as a reason not to start HRT in the first place. The strengths of this study include its large dataset and long follow-up, Kwolek said. It also calls attention to an area of women's care that too often is overlooked. Whether in primary care or gynecologic appointments, she said, 'people aren't paying as much attention to these transitions as I think they should,' Kwolek said.